Overview

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bivision Pharmaceuticals, Inc.